Catalyst Pharmaceuticals Newsroom

BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $34

Moomoo NewsApr 22 00:31 ET

BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33

MT NewswiresApr 21 11:32 ET

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Moomoo NewsMar 15 00:32 ET

Catalyst Pharmaceuticals Is Maintained at Outperform by Baird

Dow JonesMar 3 07:55 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 3 07:46 ET

Baird Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsMar 3 07:34 ET

Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsFeb 28 13:31 ET

BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $33

Moomoo NewsFeb 28 08:31 ET

H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsFeb 28 08:31 ET

Stephens Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsFeb 28 07:36 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaFeb 27 09:42 ET

Stephens & Co. Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $33 Price Target

BenzingaFeb 27 09:42 ET

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Moomoo NewsFeb 27 07:34 ET

Catalyst Pharmaceuticals Initiated With an Outperform at Baird

TipRanksFeb 4 05:18 ET

Catalyst Pharmaceuticals Price Target Announced at $28.00/Share by Baird

Dow JonesFeb 4 04:16 ET

Catalyst Pharmaceuticals Analyst Ratings

BenzingaFeb 4 04:06 ET

Baird Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $28

Moomoo NewsFeb 3 16:32 ET

Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31

Moomoo NewsJan 21 18:31 ET

Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

Moomoo NewsJan 14 07:31 ET

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

BenzingaJan 10 08:16 ET